Diabetes
Refine Search
Biosimilars
Eli Lilly has entered into a settlement agreement to resolve patent litigation with French peer Sanofi regarding its insulin glargine product, Basaglar. 29 September 2015
Pharmaceutical
French drug major Sanofi on Tuesday said the US Food and Drug Administration has accepted a New Drug Application (NDA) for its drug candidate to treat type 2 diabetes. 29 September 2015
Pharmaceutical
Merck & Co has received approval from the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for Marizev (omarigliptin) an oral, once-weekly DPP-4 inhibitor indicated for the treatment of adults with type 2 diabetes. 28 September 2015
Pharmaceutical
The US Food and Drug Administration on Friday approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve blood sugar (glucose) control in adults with diabetes mellitus. 26 September 2015
Pharmaceutical
Danish insulin giant Novo Nordisk on Friday said late stare trials for its drug to treat type 2 diabetes have been successful. 25 September 2015
Biotechnology
Announcing its first ever M&A transaction, US biotech start-up Intarcia Therapeutics says it has acquired Phoundry Pharmaceuticals, a privately held biotechnology company based in Research Triangle Park, North Carolina. 25 September 2015
Biotechnology
Taiwan-based Genovate Biotechnology has started construction for its Insulin Ecological Industrial Park in Changzhou, China, under its $1 billion biologics project to become the biggest insulin manufacturer in China. 25 September 2015
Biotechnology
US cell therapy specialist Caladrius Biosciences has entered into a collaboration agreement with Sanford Research to develop the company’s T regulatory cell therapy product candidate, CLBS03, for the treatment of adolescents with recent-onset type 1 diabetes (T1D). 24 September 2015
Pharmaceutical
With around 9% of the population suffering from diabetes, Iran represents a huge market for insulin. In fact, over the last few years the number of diabetic patients has been increasing at a compound annual growth rate (CAGR) of around 15%-16%. 24 September 2015
Pharmaceutical
Swiss pharma giant Novartis today announced the launch of “Novartis Access,” a portfolio of 15 medicines to treat chronic diseases in low- and low-middle-income countries. 24 September 2015
Pharmaceutical
C4X Discovery Holdings (on Wednesday said its drug compound Orexin-1 to treat addiction is in formal pre-clinical safety and toxicity studies ahead of the start of clinical trials. 23 September 2015
Pharmaceutical
The Iran subsidiary of Danish diabetes care giant Novo Nordisk has signed a Memorandum of Understanding with the Iranian Food and Drug Administration committing Novo Nordisk to build a local manufacturing plant for FlexPen prefilled devices in Iran. 22 September 2015
Pharmaceutical
New research has shown that Jardiance (empagliflozin) significantly reduced the risk of the combined endpoint of cardiovascular (CV) death, non-fatal heart attack or non-fatal stroke by 14% when added to standard of care in patients with type 2 diabetes at high risk of CV events. 18 September 2015
Pharmaceutical
A combination of the Danish diabetes care giant Novo Nordisk's Victoza (liraglutide), drug to treat type 2 diabetes, has demonstrated positive results, a trial has shown. 16 September 2015
Pharmaceutical
Anglo-Swedish drug major AstraZeneca announced that analysis of exenatide once weekly showed a favorable gastrointestinal tolerability profile compared to several other agents. 15 September 2015
Pharmaceutical
Presentations at the European Association for the Study of Diabetes (EASD) taking place in Stockholm, Sweden, today included several for products from Danish diabetes care giant Novo Nordisk. 15 September 2015
Pharmaceutical
French pharma company Sanofi has announced positive top-line results in the second pivotal study of insulin glargine and lixisenatide. 14 September 2015
Pharmaceutical
The US Food and Drug Association has reinforced the warning for the type 2 diabetes medicine canagliflozin (Invokana, Invokamet) related to the increased risk of bone fractures, as well as its impact on bone mineral density. 11 September 2015
Biotechnology
MetaCure, the medical technology business focussed on diabetes devices, is looking at annual revenue of $20 million following the roll-out of its flagship product, the company’s founder Professor Shlomo Ben-Haim said in an exclusive interview to The Pharma Letter. 8 September 2015
Generics
Indian drugmaker Cipla has entered into definitive agreements to acquire two USA-based companies, InvaGen Pharmaceuticals and Exelan Pharmaceutics. 4 September 2015
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze